恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

callispheres载药微球化学栓塞治疗肝内胆管癌患者有效且耐受良好-ag捕鱼平台

文字: 2020-5-6    浏览次数:359    



callispheres载药微球化学栓塞治疗肝内胆管癌患者有效且耐受良好-ctilc研究的初步结果


abstract

this study aimed to investigate the efficacy and safety of drug-eluting beads (deb) transarterial chemoembolization (tace) treatment in chinese intrahepatic cholangiocarcinoma (icc) patients.

这项研究旨在研究载药微球经动脉化学栓塞(deb-tace)治疗中国肝内胆管癌(icc)患者的有效性和安全性。


37 icc patients underwent deb-tace treatment in ctilc study (registered on clinicaltrials.gov with registry no. nct03317483)

were included in this present study. treatment response was assessed according to modified response evaluation criteria in solid tumors (mrecist). overall survival (os) was calculated from the time of deb-tace operation until the date of death from any causes. liver function change and adverse events (aes) were recorded during and after deb-tace operation.

在ctilc研究(clinicaltrials.gov上注册,注册号为nct03317483)中,共37例icc患者进行了deb-tace治疗。治疗反应评估采用修订版的实体肿瘤反应评估标准(mrecist)。生存时间(os)定义为从deb-tace开始到因任何原因引起的死亡发生。在deb-tace手术时和手术后记录肝功能变化和不良事件(ae)发生情况。


3 (8.1%) patients achieved complete response (cr) and 22 (59.5%) patients achieved partial response (pr), with objective response rate (orr) of 67.6%. after deb-tace treatment, mean os was 376 days (95%ci: 341–412 days). multivariate logistic regression analysis revealed that bilobar disease (p=.040, or: 0.105, 95% ci: 0.012–0.898) and portal vein invasion (p=.038, or: 0.104, 95% ci: 0.012–0.881) could independently predict less possibility of orr. patients with alb abnormal, tp abnormal, alt abnormal and ast abnormal were increased at 1-week post deb-tace treatment (p=.034, p=.001, p<.001, p=.006, respectively), while returned to the levels at baseline after 1 to 3 months (all p>.050). besides, most of the aes were mild including pain, fever, vomiting, and nausea in this study.

有3例(8.1%)患者获得完全缓解(cr),22例(59.5%)患者获得部分缓解(pr),客观反应率(orr)为67.6%。经过deb-tace治疗后,平均os为376天(95%ci:341–412天)。多元逻辑回归分析显示,病变累及双叶(p=0.040,or:0.105,95%ci:0.012-0.898)和门静脉侵犯(p = .038,or:0.104,95%ci:0.012-0.881)可以独立预测较低的orr。alb,tp,alt异常的患者deb-tace治疗后1周,这些值异常增加(p =0.034,p=.001,p<0.001,p=0.006,而在术后1到3个月可恢复到基线水平(所有p> 0.050)。此外,大多数不良反应(aes)轻微,包括疼痛、发烧、呕吐和恶心。


deb-tace was effective and well tolerated in treating icc patients, and bilobar disease as well as portal vein invasion were independently correlated with less probability of orr achievement.

deb-tace在治疗icc患者方面有效且耐受良好,病变累及双叶以及门静脉侵犯与较低的orr密切相关。


刘娟芳

郑州大学第一附属医院 介入科

原文链接:https://mp.weixin.qq.com/s/ixaajfyq2ukh9cx5alperw